abrdn Life Sciences Investors (abrdn Life Sciences Investors) EPS (Diluted) : $0.79 (TTM As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors EPS (Diluted)?

abrdn Life Sciences Investors's Earnings per Share (Diluted) for the six months ended in Sep. 2023 was $-0.48. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.79.

abrdn Life Sciences Investors's EPS (Basic) for the six months ended in Sep. 2023 was $-0.48. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.79.

abrdn Life Sciences Investors's EPS without NRI for the six months ended in Sep. 2023 was $-0.48. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $0.79.

During the past 3 years, the average EPS without NRIGrowth Rate was -46.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, abrdn Life Sciences Investors's highest 3-Year average EPS without NRI Growth Rate was 29.30% per year. The lowest was -46.50% per year. And the median was 3.50% per year.

abrdn Life Sciences Investors EPS (Diluted) Historical Data

The historical data trend for abrdn Life Sciences Investors's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors EPS (Diluted) Chart

abrdn Life Sciences Investors Annual Data

Trend

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EPS (Diluted)

Get a 7-Day Free Trial

-3.19

5.16

2.66

-4.26

0.79

abrdn Life Sciences Investors Semi-Annual Data
	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EPS (Diluted)	Get a 7-Day Free Trial								1.34	-3.09	-1.17	1.27	-0.48

Competitive Comparison of abrdn Life Sciences Investors's EPS (Diluted)

For the Asset Management subindustry, abrdn Life Sciences Investors's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

abrdn Life Sciences Investors's PE Ratio Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's PE Ratio distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's PE Ratio falls into.

abrdn Life Sciences Investors EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

abrdn Life Sciences Investors's Diluted EPS for the fiscal year that ended in Sep. 2023 is calculated as

Diluted EPS (A: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(22.352	-	0)	/	28.294
	=	0.79

abrdn Life Sciences Investors's Diluted EPS for the quarter that ended in Sep. 2023 is calculated as

Diluted EPS (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-11.451	-	0)	/	29.971
	=	-0.38

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.79

abrdn Life Sciences Investors (NYSE:HQL) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

abrdn Life Sciences Investors EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103

Website

https://www.abrdnhql.com

abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.

Executives

Todd Reit	director	C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher	director	600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino	director	C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor	other: Director of Adviser	C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze	other: Director of Adviser	C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc.	other: Adviser	1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick	other: Director of Adviser	C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar	officer: VP and Chief Legal Officer	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols	other: Director of Adviser	1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard	officer: President	ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy	officer: Secretary and Vice President	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari	officer: Treasurer and CFO	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson	officer: Vice President	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina	officer: Chief Compliance Officer & VP	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird	director	388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022